ICS 11.100.20 SLOVENSKÁ TECHNICKÁ NORMA Apríl 2026

STN	**Biologické hodnotenie zdravotníckych pomôcok Časť 17: Hodnotenie toxikologického rizika zložiek zdravotníckych pomôcok (ISO 10993-17: 2023/Amd 1: 2025) Zmena A1**	**STN EN ISO 10993-17/A1** 85 6510

Biological evaluation of medical devices - Part 17: Toxicological risk assessment of medical device constituents (ISO 10993-17: 2023/Amd 1: 2025)

Táto norma obsahuje anglickú verziu európskej normy.
This standard includes the English version of the European Standard.

Táto norma bola oznámená vo Vestníku ÚNMS SR č. 03/26

Obsahuje: EN ISO 10993-17:2023/A1:2025, ISO 10993-17:2023/Amd 1:2025

EUROPEAN STANDARD

NORME EUROPÉENNE

EUROPÄISCHE NORM

EN ISO 10993-17:2023/A1

December 2025

ICS 11.100.20

English Version

Biological evaluation of medical devices - Part 17: Toxicological risk assessment of medical device constituents - Amendment 1 (ISO 10993-17:2023/Amd 1:2025)

Évaluation biologique des dispositifs médicaux - Partie 17: Appréciation du risque toxicologique des constituants des dispositifs médicaux - Amendement 1 (ISO 10993-17:2023/Amd 1:2025)

Biologische Beurteilung von Medizinprodukten - Teil 17: Toxikologische Risikobewertung von Medizinproduktbestandteilen - Änderung 1 (ISO 10993-17:2023/Amd 1:2025)

This amendment A1 modifies the European Standard EN ISO 10993-17:2023; it was approved by CEN on 2 November 2025.

CEN members are bound to comply with the CEN/CENELEC Internal Regulations which stipulate the conditions for inclusion of this amendment into the relevant national standard without any alteration. Up-to-date lists and bibliographical references concerning such national standards may be obtained on application to the CEN-CENELEC Management Centre or to any CEN member.

This amendment exists in three official versions (English, French, German). A version in any other language made by translation under the responsibility of a CEN member into its own language and notified to the CEN-CENELEC Management Centre has the same status as the official versions.

CEN members are the national standards bodies of Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Republic of North Macedonia, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Türkiye and United Kingdom.

EUROPEAN COMMITTEE FOR STANDARDIZATION
COMITÉ EUROPÉEN DE NORMALISATION
EUROPÄISCHES KOMITEE FÜR NORMUNG

CEN-CENELEC Management Centre: Rue de la Science 23, B-1040 Brussels

Ref. No. EN ISO 10993-17:2023/A1:2025 E

Contents

Page

European foreword

This document (EN ISO 10993-17:2023/A1:2025) has been prepared by Technical Committee ISO/TC 194 "Biological and clinical evaluation of medical devices" in collaboration with Technical Committee CEN/TC 206 “Biological and clinical evaluation of medical devices” the secretariat of which is held by DIN.

This Amendment to the European Standard EN ISO 10993-17:2023 shall be given the status of a national standard, either by publication of an identical text or by endorsement, at the latest by June 2026, and conflicting national standards shall be withdrawn at the latest by June 2026.

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. CEN shall not be held responsible for identifying any or all such patent rights.

This document has been prepared under a standardization request addressed to CEN by the European Commission. The Standing Committee of the EFTA States subsequently approves these requests for its Member States.

For the relationship with EU Legislation, see informative Annex ZA, which is an integral part of this document.

Any feedback and questions on this document should be directed to the users’ national standards body/national committee. A complete listing of these bodies can be found on the CEN website.

According to the CEN-CENELEC Internal Regulations, the national standards organizations of the following countries are bound to implement this European Standard: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Republic of North Macedonia, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Türkiye and the United Kingdom.

Endorsement notice

The text of ISO 10993-17:2023/Amd 1:2025 has been approved by CEN as EN ISO 10993-17:2023/A1:2025 without any modification.

Annex ZA
(informative)

Relationship between this European Standard the General Safety and Performance Requirements of Regulation (EU) 2017/745 aimed to be covered

This European standard has been prepared under M/575 to provide one voluntary means of conforming to the General Safety and Performance Requirements of Regulation (EU) 2017/745 of 5 April 2017 concerning medical devices [OJ L 117] and to system or process requirements including those relating to quality management systems, risk management, post-market surveillance systems, clinical investigations, clinical evaluation or post-market clinical follow-up.

Once this standard is cited in the Official Journal of the European Union under that Regulation, compliance with the normative clauses of this standard given in Table ZA.1 and application of the edition of the normatively referenced standards as given in Table ZA.2 confers, within the limits of the scope of this standard, a presumption of conformity with the corresponding General Safety and Performance Requirements of that Regulation, and associated EFTA Regulations.

Where a definition in this harmonised standard differs from a definition of the same term set out in Regulation (EU) 2017/745, the differences shall be indicated in the Annex Z. For the purpose of using this standard in support of the requirements set out in Regulation (EU) 2017/745, the definitions set out in this Regulation prevail.

Where the European standard is an adoption of an International Standard, the scope of this document can differ from the scope of the European Regulation that it supports. As the scope of the applicable regulatory requirements differ from nation to nation and region to region the standard can only support European regulatory requirements to the extent of the scope of the European Regulation for medical devices ((EU) 2017/745).

NOTE 1 Where a reference from a clause of this standard to the risk management process is made, the risk management process needs to be in compliance with Regulation (EU) 2017/745. This means that risks have to be ‘reduced as far as possible’, ‘reduced to the lowest possible level’, ‘reduced as far as possible and appropriate’, ‘removed or reduced as far as possible’, ‘eliminated or reduced as far as possible’, ’removed or minimized as far as possible’, or ‘minimized’, according to the wording of the corresponding General Safety and Performance Requirement.

NOTE 2 The manufacturer’s policy for determining **acceptable risk** must be in compliance with General Safety and Performance Requirements 1, 2, 3, 4, 5, 8, 9, 10, 11, 14, 16, 17, 18, 19, 20, 21 and 22 of the Regulation.

NOTE 3 When a General Safety and Performance Requirement does not appear in Table ZA.1, it means that it is not addressed by this European Standard.

Table ZA.1 — Correspondence between this European Standard and Annex I of Regulation (EU) 2017/745 [OJ L 117] and to system or process requirements including those relating to quality management systems, risk management, post-market surveillance systems, clinical investigations, clinical evaluation or post-market clinical follow-up.

General Safety and Performance Requirements of Regulation (EU) 2017/745	Clause(s)/subclause(s) of this EN	Remarks/Notes
10.1 a), b), d), e), and h)	5, 6, 7, 8, 9, 10 and Annex A, Annex B, Annex C and Annex E	This document addresses the choice of materials as regards toxicity, but 10.1 is only partly covered. Flammability and mechanical or physical (e.g., surface) properties are not covered. This document provides requirements for a toxicological risk assessment process for constituents present in or on, or released from, a medical device. This risk assessment process involves the identification of substances that have the capacity to interact with biological tissues, cells or body fluids and the assessment of the nature and likelihood of any associated harm to health arising as a result of the intended use of the medical device. While such an assessment can confirm the absence of appreciable toxicological risk, it does not necessarily demonstrate the ability of a medical device or material to perform with an appropriate host response in a specific application. The toxicological risk assessment is based on the composition of the finished medical device, which is dependent, in part, on the processing materials used and the impact of processes on the materials of manufacture. Where appropriate and necessary for the risk assessment, quantitative structure-activity relationships or mathematical models can be used as part of the process specified. The document provides requirements for a process for specifying a level of exposure to a

General Safety and Performance Requirements of Regulation (EU) 2017/745	Clause(s)/subclause(s) of this EN	Remarks/Notes
		constituent of a medical device that is without appreciable harm to health and for confirming that a medical device meets the specification so defined.
10.2	5, 6, 7, 8, 9, 10 and Annex A, Annex B, Annex C and Annex E	The document addresses risks posed by contaminants and residues. However, 10.2 is only partly covered by this document, since the document does not provide requirements for design, manufacture and packaging. Although the document does not oblige manufacturers to minimize the risk posed by contaminants and residues in medical devices, it provides a means to estimate those risks and demonstrate that they have been minimized. The primary focus of this document is the risk to patients, but risks to users coming into contact with a medical device are also addressed. However the document is not applicable to medical device constituents that do not contact the body, so risks to persons involved in the transport or storage of medical devices would not normally be addressed.
10.4.1, 1st paragraph	5, 6, 7, 8, 9, 10 and Annex A, Annex B, Annex C and Annex E	The document addresses risks posed by substances, including degradation products and processing residues. However, 10.4.1 is only partly covered by this document, since the document does not provide requirements for design and manufacture, nor does it address risks associated with particles, including wear debris, from medical devices. Although this document does not oblige manufacturers to reduce as far as possible the toxicological risk posed by substances in medical devices, it provides a means to estimate those risks.

General Safety and Performance Requirements of Regulation (EU) 2017/745	Clause(s)/subclause(s) of this EN	Remarks/Notes
10.4.1, 2nd paragraph to end	5, 6, 7, 8, 9, 10 and Annex A, Annex B, Annex C and Annex E	The document is applicable for all medical devices in direct or indirect contact to the patient and includes the listed contact categories. The process specified by this document includes the identification of substances which are carcinogenic, mutagenic or toxic to reproduction or that have endocrine-disrupting properties. However, this document does not provide a method to determine whether substances, which are carcinogenic, mutagenic or toxic to reproduction of category 1A or 1B, or which are endocrine disruptors to human health, are present in concentrations above 0,1 % weight by weight (w/w) in devices, those parts thereof or those materials used therein.
10.4.2 (a), (c)	5, 6, 7, 8, 9, 10 and Annex A, Annex B, Annex C and Annex E	The process specified by this document includes the identification of substances which are carcinogenic, mutagenic or toxic to reproduction or that have endocrine-disrupting properties. Where such substances are identified, it provides a means for estimation of potential patient or user exposure to the substance that can form a basis for a justification regarding the presence of the substance and for appropriate labelling. The document also provides a means for toxicological risk assessment of alternative/substitute substances. However, the document does not include acceptability criteria or labelling requirements.

Table ZA.2 — Normative references from Clause 2 of this document and their corresponding European publications

Column 1 Reference in Clause 2	Column 2 International Standard Edition	Column 3 Title	Column 4 Corresponding European Standard Edition
ISO 10993-1:2018	ISO 10993-1:2018	Biological evaluation of medical devices — Part 1: Evaluation and testing within a risk management process	EN ISO 10993-1:2020
ISO 10993-18:2020	ISO 10993-18:2020 ISO 10993-18:2020/Amd1:2022	Biological evaluation of medical devices — Part 18: Chemical characterization of medical device materials within a risk management process	EN ISO 10993-18:2020 EN ISO 10993-18:2020/A1:2023
ISO/TS 21726:2019	ISO/TS 21726:2019	Biological evaluation of medical devices — Application of the threshold of toxicological concern (TTC) for assessing biocompatibility of medical device constituents	For applicable standard edition see Column 2
ISO 14971:2019	ISO 14971:2019	Medical devices — Application of risk management to medical devices	EN ISO 14971:2019 EN ISO 14971:2019/A11:2021

The documents listed in the Column 1 of Table ZA.2, in whole or in part, are normatively referenced in this document, i.e., are indispensable for its application. The achievement of the presumption of conformity is subject to the application of the edition of Standards as listed in Column 4 or, if no European Standard Edition exists, the International Standard Edition given in Column 2 of Table ZA.2.

NOTE 4 ISO 10993-1:2018 refers to ISO 14971:2007, which is a withdrawn document. For the use of this document EN ISO 14971: 2019/A11:2021 applies.

WARNING 1 Presumption of conformity stays valid only as long as a reference to this European standard is maintained in the list published in the Official Journal of the European Union. Users of this standard should consult frequently the latest list published in the Official Journal of the European Union.

WARNING 2 Other Union legislation may be applicable to the product(s) falling within the scope of this standard.

International Standard

ISO 10993-17

Second edition
2023-09

AMENDMENT 1
2025-11

Biological evaluation of medical devices —

Part 17: Toxicological risk assessment of medical device constituents

AMENDMENT 1

Évaluation biologique des dispositifs médicaux —

Partie 17: Appréciation du risque toxicologique des constituants des dispositifs médicaux

AMENDEMENT 1

Reference number
ISO 10993-17:2023/Amd.1:2025(en)

COPYRIGHT PROTECTED DOCUMENT

ISO copyright office
CP 401 • Ch. de Blandonnet 8
CH-1214 Vernier, Geneva
Phone: +41 22 749 01 11
Email: copyright@iso.org
Website: www.iso.org

Published in Switzerland

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular, the different approval criteria needed for the different types of ISO documents should be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2 (see www.iso.org/directives).

ISO draws attention to the possibility that the implementation of this document may involve the use of (a) patent(s). ISO takes no position concerning the evidence, validity or applicability of any claimed patent rights in respect thereof. As of the date of publication of this document, ISO had not received notice of (a) patent(s) which may be required to implement this document. However, implementers are cautioned that this may not represent the latest information, which may be obtained from the patent database available at www.iso.org/patents. ISO shall not be held responsible for identifying any or all such patent rights.

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

For an explanation of the voluntary nature of standards, the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the World Trade Organization (WTO) principles in the Technical Barriers to Trade (TBT), see www.iso.org/iso/foreword.html.

This document was prepared by Technical Committee ISO/TC 194, *Biological and clinical evaluation of medical devices,* in collaboration with the European Committee for Standardization (CEN) Technical Committee CEN/TC 206, *Biological and clinical evaluation of medical devices,* in accordance with the Agreement on technical cooperation between ISO and CEN (Vienna Agreement).

A list of all parts in the ISO 10993 series can be found on the ISO website.

Any feedback or questions on this document should be directed to the user’s national standards body. A complete listing of these bodies can be found at www.iso.org/members.html.

ISO 10993-17:2023/Amd.1:2025(en)

Biological evaluation of medical devices —

Part 17:
Toxicological risk assessment of medical device constituents

AMENDMENT 1

Clause 2, Normative references

Add a footnote to the following reference:

ISO 10993-18:2020[1], *Biological evaluation of medical devices — Part 18: Chemical characterization of medical device materials within a risk management process*